

# Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma

Information for the public

Published: 19 August 2025

[www.nice.org.uk](http://www.nice.org.uk)

Durvalumab (Imfinzi) with tremelimumab (Imjudo) is available on the NHS. It is a possible treatment for advanced or unresectable (cannot be surgically removed) hepatocellular carcinoma (liver cancer) in adults.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on liver cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [British Liver Trust](#), 0800 652 7330
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7144-2